Sharing clinical trial data on patient level: opportunities and challenges

Area of Science:

• Biostatistics
• Clinical Trials
• Data Science

Background:

• Patient-level clinical trial data sharing is a contentious issue.
• Initiatives like the European Medicines Agency's (EMA) proactive publication and the AllTrials campaign are driving change.
• The EMA's draft policy on data access highlights the evolving landscape of drug development.

Purpose of the Study:

• To discuss the implications of patient-level clinical trial data sharing.
• To identify opportunities and challenges posed by these new data sharing initiatives.
• To emphasize the need for biostatistical expertise in interpreting complex data analyses.

Main Methods:

• Review of current initiatives and policy discussions regarding clinical trial data sharing.
• Analysis of the potential impact on drug development and medical research publication.
• Exploration of biostatistical challenges, including multiplicity and interpretation of analyses.

Main Results:

• Data sharing initiatives present significant opportunities for research and synthesis.
• New challenges arise for regulatory authorities, industry, journals, and the public.
• Biostatistical expertise is crucial for managing multiplicity and interpreting multiple statistical analyses.

Conclusions:

• The trend towards sharing patient-level clinical trial data will reshape medical research.
• Addressing biostatistical complexities, such as multiplicity, is essential for robust interpretation.
• Optimizing procedural guidance and employing sophisticated analysis methods are key for regulatory decision-making.